Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEST-LATE: DAPT Duration After DES
NCT00590174Phase 4
Key facts
- Status
- Completed
- Start
- Oct 2007
- Primary completion
- Mar 2010
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- clopidogrel
- Conditions
- coronary artery disease (CAD)
01
Overview
Phase 4, randomised, open-label trial of clopidogrel in coronary artery disease (CAD) (2 arms). Primary endpoint: Composite of death or myocardial infarction at 12 months. Started Oct 2007; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Aspirin Monotherapy
Discontinue Clopidogrel, continue Aspirin
Dual Antiplatelet Therapy
Continue Aspirin and Clopidogrel
03
Who it enrols
Patients enrolled in the ZEST trial who were event-free for the first 12 months after DES implantation.
04
Endpoints
Primary
Composite of death or myocardial infarction
Secondary
All Death
Cardiac death
Myocardial infarction
Stroke
Target vessel revascularization
Target lesion revascularization
Stent thrombosis
Bleeding event
Beyond the preview
Go deeper on NCT00590174.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00590174.